Introduction
Type 2 diabetes is a complex disease that is characterized by insulin resistance in peripheral tissues and dysfunction in insulin secretion. Type 2 diabetes is a major public health problem, and its prevalence is increasing at an alarming rate worldwide. It has been estimated that 371 million people are already affected by type 2 diabetes, and the number is projected to reach 552 million by 2030 (1) .
The development of type 2 diabetes is caused by a combination of lifestyle and genetic factors (2, 3) . Some risk factors, such as diet and obesity, are under personal control; however, genetic factors are not (4) . Although the rise in type 2 diabetes prevalence can be mostly attributed to changes in diet and lifestyle, there is strong evidence of a genetic basis for type 2 diabetes (2). However, genetic risk factors have been found to have lower predictive values when compared to phenotype variables such as body mass index (BMI), familial diabetes history (FAMDB), high blood pressure (HBP), and cholesterol (CHOL) (5, 6) . Furthermore, the additive contribution of genetic studies using single nucleotide polymorphisms (SNPs) to phenotype variables was found to be almost negligible in several studies (5) (6) (7) (8) (9) (10) (11) (12) . Because numerous genetic and nongenetic risk factors interact in the causation of type 2 diabetes, the predictive ability of genetic models will likely remain modest.
At present, the clinical use of genetic testing for type 2 diabetes prediction in adults is not recommended (13) . Phenotypic risk factors have a higher predictive ability with area under the curve (AUC) values of 0.70-0.90, but these are in middle or later ages when the reversibility of factors is low. Therefore, a model to predict the risk score for type 2 diabetes in the early stages is needed. Additionally, as prediabetic individuals usually remain undiagnosed and untreated, identifying new methods using the genotype for the screening and prediction of risk factors is very important. The early prediction of risk factors may help patients to make lifestyle modifications in connection with preventable risk factors, such as obesity (14) .
Genome-wide association studies (GWASs) have been widely used to investigate the role of the genotype in the development of diseases. Although many studies have been conducted to uncover the heritability of type 2 diabetes, only a small proportion of genetic heritability can be explained by the variants identified. GWASs have shown significant genome-wide associations with type 2 diabetes at 44 susceptibility loci so far (15) . The current type 2 diabetes risk variants explain only about 5%-10% of the genetic basis of type 2 diabetes; much of the genetic basis remains unexplained (16, 17) .
Most of these studies used logistic regression for the analysis of genetic variables. However, the maximum number of SNPs used was 42, and C-statistics results (AUC) for the genotype were lower than 0.60 (5) (6) (7) (8) (9) (10) (11) (12) . In the course of our GWAS analysis of Nurses' Health Study (NHS) and Health Professionals' Follow-up Study (HPFS) data, we realized that sensitivity, specificity, and C-statistics increased with the number of SNPs. As we used genotype data for the whole genome instead of a finite number of SNPs, unlike previous studies, a high number of SNPs were included in the analysis. The highest prediction risk scores and AUCs for type 2 diabetes in the literature, even when phenotype studies are included, were achieved in this study using the 798 SNPs selected with P-values of less than 1.0E-3 for the model. Our findings demonstrate the importance of genotype in the prediction of type 2 diabetes, which has been previously disregarded.
Materials and methods

Study population
The NHS and HPFS are well-characterized cohorts of nurses and health professionals, conducted in order to identify novel genetic factors that contribute to type 2 diabetes through large-scale, GWASs and to investigate the role of environmental exposure on the development of type 2 diabetes. The NHS and HPFS cohorts are part of the Gene Environment Association Studies initiative (GENEVA, http://www.genevastudy.org). The NHS was established in 1976, and the HPFS study was started in 1986. Participants of the NHS and HPFS completed a mailed questionnaire on their medical history and lifestyle. Participants meeting the following criteria were excluded from the study: 1) those with other types of diabetes (65 NHS, 68 HPFS); 2) those belonging to races other than white (61 NHS, 100 HPFS); 3) HapMap controls (45 NHS, 29 HPFS); and 4) first-degree relatives (15 NHS, 14 HPFS) . The final sample included 3248 (1769 controls and 1479 cases) for the NHS and 2391 (1277 controls and 1114 cases) for the HPFS. The current analysis includes SNPs mapped to chromosomes 1 through 23, as annotated based on the Affymetrix Genome-Wide Human SNP Array 6.0 (GeneChip 6.0).
homozygotes separately for analysis. We evaluated model discrimination by using C-statistics (areas under receiver operating characteristic curves, ROC-AUCs), which were calculated for the predicted risk of the logistic regression model.
We used SNPs with P-values of less than 1.0E-3. There were 886 SNPs with P-values below this level. However, we excluded SNPs if the missing allele number was greater than 50 (patients), except for rs10739592, since it had the lowest P-value (2.08E-14). It had 99 missing alleles. To fill in the missing alleles, we used the Amelia toolbox for imputation (18) . The result of the imputation was validated by comparing 'before' and 'after' P-values of SNPs and observing the relative distribution density of the original data set and the imputed data set.
Results
The clinical characteristics of the participants
The clinical characteristics of the study populations are presented in Table 1 . We performed a genome-wide analysis of NHS and HPFS participants. The frequency distribution of the P-value of the SNPs is given in Table  2 . The P-values of 886 SNPs were less than 1.0E-03. The distribution of P-values for all SNPs (642,576) versus chromosomal distribution is shown as a Manhattan plot in Figure 1 . Chromosomes, P-values, odds ratios, and MAF values of 798 SNPs are provided in the Appendix (on the journal's website). Quantile-quantile (QQ) plots of P-values of SNPs are given against the expected P-values in Figure 2 . We accepted 1.0E-3 as the threshold level to determine which SNPs would be included in the analysis ( Figure 2 ). Initially, 886 SNPs were considered; after a quality check for missing criteria, 798 SNPs were used.
BLR analysis of phenotype
The analysis results of phenotype variables of the NHS and HPFS data sets are presented in Table 2 . The summary of BMI is also listed in Table 3 as a continuous variable. As noted in Section 2, BMI was converted to a binary form before BLR analysis. Type 2 diabetes patients had significantly higher BMIs than the controls. BMI was strongly associated with type 2 diabetes; the odds ratio for BMI was 3.86. Other important phenotypes were FAMDB, HBP, and CHOL. Their P-values and odds ratios are also given in Table 4 . The combined effect of these 4 phenotype variables yielded an overall classification of 70.7% and an AUC of 0.77. We also compared rs10739592, which had the lowest P-value in GWAS analysis, with phenotypic variables. It should be noted that rs10739592 alone (OR: 1.34, P-value: 2.08E-14) increased the overall prediction by only 2.84%. The composite effect of phenotypic variables was less than the sum of the individual effects of each variable alone due to the effect of overlap.
We were able to predict individual risk scores using the following formula with constants obtained from logistic regression analyses of familial diabetes history, high blood pressure, cholesterol, and BMI. 
P=
The C-statistics (AUC) value for the 4 phenotype variables was found to be 0.77 ± 0.003.
BLR analysis of genotype
Because the number of SNPs (798) is high and is unusual for BLR, as reported in the literature, we used a different approach to evaluate the effect of genotype on prediction scores and AUC. First, we grouped SNPs according to their P-values. Three groups of SNPs with P-values of less than 1.0E-4 yielded a maximum prediction score of 67.4% and an AUC of 0.735; 680 SNPs with P-values between 1.0E-04 and 1.0E-03 yielded a prediction score of 87.7% and an AUC of 0.947. When we used an incremental approach, the first 3 groups containing 118 SNPs with P-values of less than 1.0E-4 yielded prediction scores that were lower than that of the fourth group (Table 5) . This showed that more SNPs should be included for higher prediction rates and explained why previous studies in the literature that used a maximum of 40 SNPs obtained lower predictive values. In addition, we tested how various threshold levels in BLR analysis affected the prediction score and AUC (Table  6 ). The threshold level was chosen to be 0.5 by default in BLR analysis. When the threshold level increases, negative predictive value increases, positive predictive value decreases, and AUC does not change (Table 6) .
We also investigated the additive contribution of phenotypes to the model built from genotyping data. The addition of 4 phenotypes (BMI, FAMDB, CHOL, and HBP) increased the prediction score from 90.0% to 92.9% and the AUC from 0.965 to 0.980 ( Figure 3 ).
In addition, we found important differences between females and males in SNPs corresponding to the transcription factor-7-like 2 (TCF7L2) gene (Table 7) . We found that the TCF7L2 gene was more determinative in males than in females. Although the TCF7L2 gene is one of the most significant genetic marker associated with type 2 diabetes mellitus risk (19) , there is no information in the literature about the relationship between the TCF7L2 gene and sex. This finding is important when interpreting literature on interethnic differences that do not mention sex.
Discussion
Development of genotype-based prediction will help us in the early prediction, identification, and prevention of type 2 diabetes. We showed that genotype-based predictions for type 2 diabetes yielded as high a score as phenotype-based methods. We obtained 90.0% prediction correctness, and the AUC was 0.965 with only genotype (SNP) variables. According to our knowledge, this is the highest score reported in the literature for risk prediction of type 2 diabetes.
GWAS has facilitated the understanding of the genetic basis of complex traits; it is a powerful method for the detection of genetic variations that predispose individuals GWAS analysis. The x-axis is -log 10 of the expected P-values and the y-axis is -log 10 of the observed P-values. Detaching point from the expected -log 10 is nearly 1.0E-3. to complex chronic diseases. GWAS has provided many useful insights into the pathophysiology of type 2 diabetes by enabling the identification of novel susceptibility loci that were not identified by classical approaches. However, for most of the identified type 2 diabetes susceptibility loci, the causal variants and molecular mechanisms for diabetes risk are unknown. Our findings do not reject the importance of susceptibility loci for causal variants, but rather provide more accurate risk prediction. It is also important to remember that the effect sizes found for SNPs thus far are not a reflection of their biological or clinical significance.
Although their individual predictive values may be small, SNPs as a profile might point to important biological pathways that could be targeted for therapeutic intervention. Fortunately, the incidence of type 2 diabetes can be delayed or prevented by maintaining healthy lifestyle behaviors (14) . The early identification of population subgroups that are at particularly high risk for type 2 diabetes might facilitate the targeting of prevention efforts to those who might benefit from them the most. Until these findings, genetic associations have not appeared to improve type 2 diabetes risk prediction, which has already been achieved through clinical risk predictors alone.
In the time since the first GWAS data were published in 2007 by the Wellcome Trust Case Control Consortium (20), significant progress has been made and much information has been obtained from GWASs. However, GWAS-based studies to improve clinical decisions are still in their initial stages (21). Previous studies have focused mostly on causative loci rather than the entire risk prediction approach. In addition, the results of risk prediction models are not satisfactory for type 2 diabetes. Nearly 40 susceptible loci have been identified in European and Asian populations, but the heritability of type 2 diabetes remains largely unexplained (22). Only ~10% of the known type 2 diabetes heritability could be explained by the results of a European twin study (23). This evidence suggests that information on a large portion of heritability is missing. Since a statistical P-value of 5 × 10 -8 is generally accepted for genome-wide significance (24), previous studies did not use SNPs that had P-values greater than this. Several limitations of the current approach for GWASs in revealing the missing heritability information have been proposed. One limitation is that the accepted importance threshold level for GWASs (P < 5 × 10 -8 ) may produce type 2 errors (false-negative results). Therefore, many important loci could be obscured among other loci having only borderline associations. In addition, Imamura et al. suggested that the other reason for the low percentage of genetic contribution might be the omission of susceptibility variants that have an MAF value of less than 1% (22). However, our findings do not agree with these suggestions. In this study, we used SNPs that had P-values of greater than 5 × 10 -8 , accepted 5% as the threshold for MAF, and thereby obtained a higher risk prediction score. The most important reason for the low genetic contribution reported so far is that the use of a small number of SNPs for analysis fails to yield a sufficient composite risk score. We proposed that SNPs that have P-values of less than the detaching point of a distribution (in QQ plot), 1.0E-3 in our study, could contribute to risk prediction. Furthermore, Imamura et al. (8) , the Framingham Offspring Study I (9), the Whitehall II study (10) , and the GoDARTS Study (26). These studies examined loci ranging in number from 11 to 20 that were associated with type 2 diabetes. The results of these analyses showed no clear improvement in predictive power when adding the genetic risk score to the established risk prediction models by using phenotypic variables such as age, sex, family history, BMI, fasting glucose level, systolic blood pressure, and lipid profile. Basic demographic, clinical, and laboratory predictors have C-statistics (AUC) ranging from 0.66 in the Rotterdam Study (11) to 0.90 in the Framingham Offspring Study I (9). The C-statistic improves from 0.903 to 0.906 with the addition of a 40-SNP score to the clinical model in the Framingham Offspring Study II (7) and from 0.74 to 0.75 in the larger Malmö Preventive Project (8) . In other studies, adding genetic information to phenotypebased risk models did not improve discrimination and showed a maximum increase of only 2% over phenotype in ROC curves (6, 10, 26) . AUC values were equal to or lower than 0.60 for genetic variants alone in these studies (9) (10) (11) 26) . Therefore, phenotype scores were found to be superior to the scores achieved thus far by using genotype alone.
Genotype-based risk prediction may work better in younger individuals. In the Framingham Offspring II study, the addition of a 40-SNP score to a full clinical model achieved better net reclassification improvement (NRI) among those younger than 50 years old (7) . However, the degree of prediction scores obtained from genotype is still below the widely accepted clinical prevention target. The greater contribution of genotype over the prediction value of phenotype for patients at a younger age is expected since phenotype variables are more overt only at middle age or older. The most desirable risk prediction method is one with a higher prediction value at an early age, even in childhood. Therefore, our findings provide an opportunity for risk prediction of type 2 diabetes with high accuracy at an early stage.
A limitation on the use of phenotypic variables is the reduced range of ages and follow-up durations for type 2 diabetes genetic prediction. In previous studies, participants with baseline ages were generally in middle adulthood, and the follow-up period was around 10 years. However, we need a model that can estimate the risk earlier, which should be validated at a young age with a longer prediction time horizon to help achieve early prevention. As noted above, in the Framingham Offspring Study II, the 40-SNP genotype risk score significantly improved NRI in younger participants but not in older ones. Here, we show that genetic risk prediction alone using 798 SNPs could yield higher risk prediction for type 2 diabetes.
Due to the low predictive value of the genetic susceptibility loci of type 2 diabetes so far, alternative GWAS strategies, such as enrichment of genetic effects for improving predictive power (i.e. selecting more severe cases, early onset of disease, and family history of type 2 diabetes), and original GWAS study designs (such as response to an antidiabetic treatment or type 2 diabetes in the presence of extreme obesity) (15, 27 ) have been proposed. Complementary epigenomic approaches such as DNA methylation studies have also been proposed in addition to GWAS (27). However, our strategy of using more SNPs may provide greater risk prediction for type 2 diabetes; therefore, the need for a sophisticated approach to risk prediction could be reviewed. Our approach might be combined with epigenomic, environmental, or other enrichment methods for further insight into type 2 diabetes etiology.
In the future, follow-up studies with a reasonable time period should be designed to evaluate the development of type 2 diabetes using the genotype-based risk prediction value from our study. We were able to calculate individual risk scores using the constants of the present study obtained through analysis. Our findings should be validated by comparing the cumulative type 2 diabetes incidence in low-and high-risk groups in a follow-up study. In addition, interethnic differences should be reviewed from the perspective of our results, since some GWAS studies did not mention the sex of the participants (28,29). Furthermore, our prediction strategy could also be tested for treatment success of type 2 diabetes by establishing a pharmacogenetic investigation of a genomewide approach. In a previous study, it was found that a SNP, rs11212617, at a locus containing the ataxia telangiectasia mutated gene could explain 2.5% of the variance in the metformin response (30). Variance greater than this can probably be explained using the composite SNP score approach. Translation of the findings of the present study will provide a gateway into personalized preventive and therapeutic medicine.
In conclusion, we found that genotype-based risk prediction could yield higher risk prediction values when a sufficient number of SNPs are used. This could enable early risk prediction for type 2 diabetes. The growing importance of the threshold P-value in GWAS analysis should be reviewed, depending on the investigation field. Our findings open up new horizons for translating GWAS findings into improved care for patients with diabetes. The value of genotype-based risk prediction alone or in combination with phenotypic variables should be further investigated in follow-up studies for validation. Appendix. Chromosomes, P-values, odds ratios, and MAF values of 798 SNPs. 
